BMA Advisory on Semaglutide Prescribing Guidelines
General practitioners must now obtain written confirmation of funding from their local Integrated Care Boards before prescribing semaglutide to reduce cardiovascular disease risk. The British Medical Association issued this directive to protect practices from assuming the administrative and clinical burden of a high-volume service without adequate resources. While NICE recommends the drug for adults with established cardiovascular disease and a BMI of at least 27, this clinical guidance does not automatically translate into a core obligation under the General Medical Services contract.
Existing cardiovascular disease indicators within the Quality and Outcomes Framework do not cover this specific treatment pathway. This creates a significant gap between clinical recommendation and the practical capacity of local surgeries. The BMA emphasizes that any shift of responsibility into primary care requires a formal commissioning arrangement. Without this, practices risk stretching their internal capacity to a breaking point.
The Financial and Operational Strain on Primary Care
Approximately 1.2 million people are eligible for semaglutide treatment under the updated NICE criteria. Integration of this rollout is expected to be funded by ICBs within a 90-day window following the official guidance publication. Still, the BMA warns that general practice is not equipped to manage this influx without dedicated financial support for patient identification, dose titration, and longitudinal monitoring. The administrative weight of coding and recalls remains a specific concern for practice managers.
Practices are urged to seek explicit service specifications that detail clinical time, infrastructure support, and indemnity coverage. If the funding does not cover the full scope of work, the BMA advises that doctors should resist routine prescribing. Ensuring that prescribing strictly aligns with NICE criteria is another critical safeguard highlighted in the latest guidance. The goal is to prevent a scenario where clinicians are forced to manage high-cost, high-demand treatments using existing, already overstretched resources.
Future Implications for Cardiovascular Care
Semaglutide remains a potent tool for secondary prevention. Its ability to reduce major adverse cardiovascular events is proven by clinical data. However, the disconnect between medical potential and bureaucratic reality threatens the effectiveness of this rollout. The BMA stance serves as a reminder that healthcare delivery is as much about infrastructure as it is about pharmaceutical innovation. Commissioners must now address these operational demands to avoid further friction between primary care and regional health boards.
What happens next depends on how quickly ICBs respond to the BMA requirements. Practices that fail to secure written confirmation risk absorbing the costs and workload of a new service that is technically outside their standard responsibilities. As patient demand grows, the pressure on local leaders to clarify funding paths will intensify. Observers should watch for how many regions establish locally commissioned services versus those that attempt to shift the burden onto existing GP capacity.